94 related articles for article (PubMed ID: 462424)
1. Measurement of the heparin neutralizing capacity of protamine.
Graham DT; Pomeroy AR; Smythe DB
Thromb Haemost; 1979 May; 41(3):583-9. PubMed ID: 462424
[TBL] [Abstract][Full Text] [Related]
2. The determination of the heparin neutralising capacity of protamine using acridine orange fluorescence.
Edwards HE; Navaratnam S; Allen JC; Phillips GO
Thromb Haemost; 1980 Jun; 43(2):108-11. PubMed ID: 7455967
[TBL] [Abstract][Full Text] [Related]
3. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
Chang LC; Lee HF; Chung MJ; Yang VC
Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
Bhargava AS; Heinick J; Günzel P
Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
[TBL] [Abstract][Full Text] [Related]
5. [Collaborative study of Japanese Pharmacopoeia Heparin Sodium Reference Standard (Control 871)].
Yomota C; Hasegawa R; Komuro T; Okada S; Kimura T
Eisei Shikenjo Hokoku; 1989; (107):148-51. PubMed ID: 2636920
[TBL] [Abstract][Full Text] [Related]
6. Strategies for improving the functionality of an affinity bioreactor.
Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
[TBL] [Abstract][Full Text] [Related]
7. Heparin-protamine does not aggravate local LPS-provoked leukocytic inflammation in vivo.
Schramm R; Nickels RM; Harder Y; Langer F; Menger MD; Schäfers HJ
Thorac Cardiovasc Surg; 2006 Dec; 54(8):506-11. PubMed ID: 17151963
[TBL] [Abstract][Full Text] [Related]
8. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
9. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant monitoring and neutralization during open heart surgery--a rapid method for measuring heparin and calculating safe reduced protamine doses.
Umlas J; Taff RH; Gauvin G; Swierk P
Anesth Analg; 1983 Dec; 62(12):1095-9. PubMed ID: 6650893
[TBL] [Abstract][Full Text] [Related]
11. Reversal of protamine of the prolonged response to intrapulmonary heparin.
Wright CJ; Mahadoo J; Jaques LB
Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
[TBL] [Abstract][Full Text] [Related]
12. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT).
Bode AP; Castellani WJ; Hodges ED; Yelverton S
Thromb Haemost; 1991 Aug; 66(2):213-7. PubMed ID: 1771614
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
14. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
Meager A; Das RG
J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
[TBL] [Abstract][Full Text] [Related]
15. A collaborative study of heparins from different sources.
Bangham DR; Woodward PM
Bull World Health Organ; 1970; 42(1):129-49. PubMed ID: 5309510
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a replacement batch for heparin sodium biological reference preparation.
Behr-Gross ME; Daas A
Pharmeuropa Bio; 2007 Dec; 2007(1):19-28. PubMed ID: 18413135
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of protamine sulfate are dependent on the presence and type of circulating heparin.
Fiser WP; Fewell JE; Hill DE; Barnes RW; Read RC
J Thorac Cardiovasc Surg; 1985 Jan; 89(1):63-70. PubMed ID: 3965817
[TBL] [Abstract][Full Text] [Related]
18. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effect of heparin, chondroitin, dextran and protamine on the virulence of pseudorabies virus (Suid herpesvirus 1).
Ramos-Kuri M; Kretschmer RR; Espinosa-Larios EL; Aguilar-Setién A
Arch Invest Med (Mex); 1990; 21(1):29-33. PubMed ID: 2171447
[TBL] [Abstract][Full Text] [Related]
20. Heparin monitoring during cardiopulmonary bypass.
Saleem A; Shenaq SS; Yawn DH; Harshberger K; Diemunsch P; Mohindra P
Ann Clin Lab Sci; 1984; 14(6):474-9. PubMed ID: 6508227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
